|
|
Volumn 108, Issue 19, 2003, Pages
|
|
Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ANTICOAGULANT AGENT;
ANTITHROMBOCYTIC AGENT;
IMMUNOGLOBULIN F(AB) FRAGMENT;
MONOCLONAL ANTIBODY;
ACUTE DISEASE;
AGED;
COHORT ANALYSIS;
COMPARATIVE STUDY;
CORONARY ARTERY BLOOD FLOW;
CORONARY ARTERY DISEASE;
CORONARY BLOOD VESSEL;
DRUG EFFECT;
FEMALE;
HUMAN;
INTRAARTERIAL DRUG ADMINISTRATION;
MALE;
MIDDLE AGED;
MULTIMODALITY CANCER THERAPY;
NOTE;
PATHOPHYSIOLOGY;
TRANSLUMINAL CORONARY ANGIOPLASTY;
ACUTE DISEASE;
AGED;
ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY;
ANTIBODIES, MONOCLONAL;
ANTICOAGULANTS;
COHORT STUDIES;
COMBINED MODALITY THERAPY;
CORONARY CIRCULATION;
CORONARY DISEASE;
CORONARY VESSELS;
FEMALE;
HUMANS;
IMMUNOGLOBULIN FAB FRAGMENTS;
INFUSIONS, INTRA-ARTERIAL;
MALE;
MIDDLE AGED;
PLATELET AGGREGATION INHIBITORS;
MLCS;
MLOWN;
|
|
EID: 0642367056
PISSN: None
EISSN: 15244539
Source Type: Journal
DOI: 10.1161/01.cir.0000099921.71299.d9 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
